Please read my comment at the end of this article. This is NOT new.
To date, mainstream researchers, authorities, & doctors have denied the pleomorphism of borrelia.
Pleomorphism is borrelia‘s ability to shape-shift – necessitating different medications to kill ALL the forms. To date there are essentially FOUR forms: spirochetal, cell wall, non cell wall (cyst), and biofilm. Doxy only kills 2 forms, the spirochetal and cell wall forms – leaving biofilms and non cell wall forms to proliferate. I’ve written about the fear of doxy throwing the spirochetal form into the cyst form often and that Alzheimer’s, dementia, and other neurological-brain diseases may be the result of this flawed treatment approach: https://madisonarealymesupportgroup.com/2016/02/13/lyme-disease-treatment/Within this lengthy article showing appropriate treatment for borrelia, is a study by Eva Sapi showing that using the mono-therapy of doxy DOES throw the spirochetal form into the noncell wall form to reemerge later – at least in vitro. https://www.frontiersin.org/articles/10.3389/fmicb.2019.00690/full? This more recent article states the same.
Recently, an article was published taking pleomorphism into account and the ability of a 3-drug combination to eradicate it – at least in mice: https://madisonarealymesupportgroup.com/2019/04/24/three-antibiotic-cocktail-clears-persister-lyme-bacteria-in-mouse-study/. I also have heard directly from Lyme literate doctors that clinically they are seeing vast improvement in patients with this cocktail.
One of those drugs (Dapsone) is a mycobacterium drug used for leprosy: https://madisonarealymesupportgroup.com/2016/10/09/mycobacterium-drugs-for-ld/
Lastly, this article explains the faulty supposition that only 10-20% have continuing symptoms (PTLDS). Microbiologist Holly Ahern argues convincingly that it’s more like 60% that have chronic/persistent symptoms: https://madisonarealymesupportgroup.com/2019/02/25/medical-stalemate-what-causes-continuing-symptoms-after-lyme-treatment/ Excerpt:
- 10-20% are promptly diagnosed and treated but still have symptoms. This is PTLDS.
- 30-40% are NOT promptly diagnosed. After finally getting diagnosed & treated, they still have symptoms. This subgroup has no specific label but it has been referred to as “chronic Lyme disease,” or CLD.
- Combining these two subgroups implies that up to 60% of people with Lyme disease will experience chronic illness as a result of this tick-borne disease.
60% OF LYME PATIENTS END UP WITH CHRONIC SYMPTOMS
So, this “New form of Lyme” is already 60% of us. We live this sucker out every day, and proper treatment is critical.
I had an advocate contact me and state the Newsweek article is setting everyone up for a future Lyme vaccine. Unfortunately, this type of fear-mongering is happening all around us: https://madisonarealymesupportgroup.com/2019/03/15/medical-doctor-of-50-years-current-measles-hysteria-not-based-on-science-but-scientism-a-quasi-religious-faith-in-vaccines/ You have to ask yourself, why the fear tactics? Short answer: power & money. Science has been hijacked: https://madisonarealymesupportgroup.com/2017/01/28/sit-down-science/
More on the Lyme vaccine: https://madisonarealymesupportgroup.com/2018/07/22/why-we-care-so-strongly-about-a-potential-lyme-vaccine/ (Many more links within this one)
Let’s talk about the Lyme vaccine pulled from the market due to “lack of demand.”
Did you know that the LYMERIX vaccine caused 640 emergency room visits, 34 life threatening reactions, 77 hospitalizations, 198 disabilities, and 6 deaths? In a vile cesspool of conflicts of interest are university patent holders, drug companies, and the FDA itself as another patent holder. It generated 40 million dollars before it was yanked. (2008, Drymon)
http://www.yourlawyer.com/topics/overview/lymerix One doctor stated that 21 patients developed severe arthritis after receiving the LYMERIX vaccine.
http://www.lymediseaseassociation.org/index.php/about-lyme/controversy/vaccine/261-lymerix-meeting “Given that Dr. Marks lead the clinical trials for Lymerix’s competitor, the OspA vaccine produced and then abandoned by Aventis Pasteur, his conclusions mean a lot. “In my opinion,” he told FDA officials, “there is sufficient evidence that Lymerix is causally related to severe rheumatologic, neurologic, autoimmune, and other adverse events in some individuals. This evidence is such as to warrant a significantly heightened degree of warnings and possible limitations or removal from marketing of Lymerix.”
https://madisonarealymesupportgroup.com/2017/01/26/lyme-vaccine-to-be-tested-on-humans/ The biological mechanism hypothesis was that the outer surface protein A (OspA), which was the antigenic component of the LYMErix vaccine, induced autoimmunity in genetically susceptible individuals, including high levels of autoantibody to OspA in their synovial fluid.
Dr. Stricker states:
Another Lyme OspA Vaccine Whitewash
The meta-analysis by Zhao and colleagues comes to the conclusion that “the OspA vaccine against Lyme disease is safe and its immunogenicity and efficacy have been verified.” The authors arrive at this sunny conclusion by excluding 99.6% of published articles that demonstrate potential problems with the OspA vaccine. Furthermore, the authors ignore peer-reviewed studies, FDA regulatory meetings and legal proceedings that point to major problems with OspA vaccine safety (1-3). This whitewash bodes ill for future Lyme vaccine candidates because it fosters disregard for vaccine safety among Lyme vaccine manufacturers and mistrust among potential Lyme vaccinees.